Evidence map›Paper›PMID 37353554›Full record

ArticleCommunications chemistry2023

An end-to-end deep learning framework for translating mass spectra to de-novo molecules.

Eleni E Litsa, Vijil Chenthamarakshan, Payel Das, Lydia E Kavraki

Abstract read
In one paragraph

Article in Communications chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Eleni E LitsaDepartment of Computer Science, Rice University, Houston, TX, USA.
Vijil ChenthamarakshanIBM Research, IBM Thomas J. Watson Research Center, Yorktown Heights, NY, USA.ORCID http://orcid.org/0000-0001-7830-5777
Payel DasIBM Research, IBM Thomas J. Watson Research Center, Yorktown Heights, NY, USA. daspa@us.ibm.com.ORCID http://orcid.org/0000-0002-7288-0516
Lydia E KavrakiDepartment of Computer Science, Rice University, Houston, TX, USA. kavraki@rice.edu.ORCID http://orcid.org/0000-0003-0699-8038

Funding

PROTEAN-CR: Proteomics Toolkit for Ensemble Analysis in Cancer ResearchU01CA258512 · NCI · RICE UNIVERSITY · PI KAVRAKI, LYDIA E., LIZEE, GREGORY A · 2021 to 2023
$1.2M
NCI NIH HHS U01 CA258512
6 · The paper itself

Abstract

Elucidating the structure of a chemical compound is a fundamental task in chemistry with applications in multiple domains including drug discovery, precision medicine, and biomarker discovery. The common practice for elucidating the structure of a compound is to obtain a mass spectrum and subsequently retrieve its structure from spectral databases. However, these methods fail for novel molecules that are not present in the reference database. We propose Spec2Mol, a deep learning architecture for molecular structure recommendation given mass spectra alone. Spec2Mol is inspired by the Speech2Text deep learning architectures for translating audio signals into text. Our approach is based on an encoder-decoder architecture. The encoder learns the spectra embeddings, while the decoder, pre-trained on a massive dataset of chemical structures for translating between different molecular representations, reconstructs SMILES sequences of the recommended chemical structures. We have evaluated Spec2Mol by assessing the molecular similarity between the recommended structures and the original structure. Our analysis showed that Spec2Mol is able to identify the presence of key molecular substructures from its mass spectrum, and shows on par performance, when compared to existing fragmentation tree methods particularly when test structure information is not available during training or present in the reference database.

Identifiers

PMID37353554
PMCPMC10290119

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.